PatientsVille.com Logo

PatientsVille

Estreva Side Effects

Common Estreva Side Effects


The most commonly reported Estreva side effects (click to view or check a box to report):

Meningioma (3)
Visual Acuity Reduced (2)
Pulmonary Arterial Hypertension (2)
Subclavian Vein Thrombosis (1)
Retinal Vein Occlusion (1)
Thoracic Outlet Syndrome (1)
Transient Ischaemic Attack (1)
Idiopathic Thrombocytopenic Purpura (1)
Irritability (1)
Renal Failure (1)
Thrombocytopenia (1)
Optic Neuritis (1)
Meningitis Aseptic (1)
Myositis (1)
Off Label Use (1)
Macular Oedema (1)
Leukocytoclastic Vasculitis (1)
Pulmonary Embolism (1)
Jugular Vein Distension (1)
Rash Scarlatiniform (1)

➢ More



If you or someone in your family has experienced a serious side effect to a health product, you are encouraged to report the experience to your health care professional (e.g. physician, pharmacist). You could also complete a copy of the side effect reporting form or report your side effect to FDA.

Side effects reports are analyzed to discover potential health product safety signals. Some important reactions may take an extremely long time to develop or occur infrequently. Continued monitoring of adverse reactions is thus essential to maintain a comprehensive safety and effectiveness profile of health products.

Estreva Side Effects Reported to FDA

The following Estreva reports list potential signals of serious risks and new safety information that were identified using the FDA Adverse Event Reporting System (FAERS).
FAERS is a database that contains information on adverse event and medication errors reports submitted to FDA by healthcare professionals (such as physicians, pharmacists, nurses and others), consumers (such as patients, family members, layers and others) and manufacturers.


The appearance of Estreva on this list does not mean that FDA has concluded that the drug has the listed risk. It means that FDA has identified a potential safety issue, but it does not mean that FDA has found a causal relationship between the drug and the listed risk.
Retinal Vein Occlusion, Macular Oedema, Visual Acuity Reduced, Eye Haemorrhage
This is a report of a 53-year-old female patient (weight: NA) from DE, suffering from the following symptoms/conditions: NA, who was treated with Estreva 0.1% Gel (dosage: 2 Dosage Forms Daily; 1 Dosage Form = 1 Puff, start time: NS), combined with: NA. and developed a serious reaction and side effect(s). The consumer presented with:
  • Retinal Vein Occlusion
  • Macular Oedema
  • Visual Acuity Reduced
  • Eye Haemorrhage
which developed after the beginning of treatment. This case can indicate the possible existence of increased vulnerability to Estreva 0.1% Gel treatment in female patients, resulting in retinal vein occlusion side effect. The patient was hospitalized and became disabled.

Hepatic Adenoma
This report suggests a potential Estreva 0.1% Gel Hepatic Adenoma side effect(s) that can have serious consequences. A 48-year-old female patient (weight: NA) from FR was diagnosed with the following symptoms/conditions: NA and used Estreva 0.1% Gel (dosage: NA) starting 200806. Soon after starting Estreva 0.1% Gel the patient began experiencing various side effects, including:
  • Hepatic Adenoma
Drugs used concurrently:
  • Lutenyl 3.75 Mg
The patient was hospitalized. Although Estreva 0.1% Gel demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as hepatic adenoma, may still occur.

Pulmonary Embolism, Agranulocytosis, Cough, Dyspnoea
This Pulmonary Embolism, Agranulocytosis, Cough, Dyspnoea problem was reported by a health professional from FR. A 53-year-old female patient (weight: NA) was diagnosed with the following symptoms/conditions: hirsutism,bipolar disorder. On 2006 this consumer started treatment with Estreva (dosage: 2 Dosage Forms Daily;). The following drugs were being taken at the same time:
  • Zyprexa (15 Milligram Daily;)
  • Androcur (.5 Dosage Forms Daily;)
  • Lepticur 10 Mg (1 Dosage Forms Daily;)
When commencing Estreva, the patient experienced the following unwanted symptoms/side effects:
  • Pulmonary Embolism
  • Agranulocytosis
  • Cough
  • Dyspnoea
The patient was hospitalized.Although all drugs are carefully tested before they are licensed for use, they carry side effect risks. Some side effects, such as pulmonary embolism, may become evident only after a product is in use by the general population.

Blood Oestrogen Decreased, Depressed Mood
This is a report of a 59-year-old female patient (weight: NA) from DE. The patient developed the following symptoms/conditions: NA and was treated with Estreva 0,1% Gel (dosage: NA) starting Mar 28, 2013. Concurrently used drugs:
  • Black Cohosh
Soon after that, the consumer experienced the following side effects:
  • Blood Oestrogen Decreased
  • Depressed Mood
This opens a possibility that Estreva 0,1% Gel treatment could cause the above reactions, including blood oestrogen decreased, and some female subjects may be more susceptible.


Transient Ischaemic Attack
A 58-year-old female patient (weight: NA) from FR with the following symptoms/conditions: NA started Estreva 0.1 % treatment (dosage: NA) on Mar 01, 2013. Soon after starting Estreva 0.1 % treatment, the subject experienced various side effects, including:
  • Transient Ischaemic Attack
Concurrently used drugs:
  • Estima 100 Mg
  • Cortancyl (12.5 Milligram Daily;)
  • Diffu K
  • Esomeprazole
  • Kenzen 8 Mg
  • Crestor 5 Mg
  • Levothyrox (25 Microgram Daily;)
The patient was hospitalized. This finding indicates that some female patients could be more vulnerable to Estreva 0.1 %.

Deep Vein Thrombosis, Subclavian Vein Thrombosis, Jugular Vein Distension, Thoracic Outlet Syndrome
A 49-year-old female patient from FR (weight: NA) experienced symptoms, such as: NA and was treated with Estreva(dosage: NA). The treatment was initiated on NS. After that a consumer reported the following side effect(s):
  • Deep Vein Thrombosis
  • Subclavian Vein Thrombosis
  • Jugular Vein Distension
  • Thoracic Outlet Syndrome
Concurrently used drugs, which potentially could have contributed to side effect(s) or affected Estreva efficacy:
  • Colprone 5 Mg
The patient was hospitalized.

Erythema Nodosum, Myositis, Off Label Use
In this report, Estreva was administered for the following condition: endometriosis.A 33-year-old female consumer from FR (weight: NA) started Estreva treatment (dosage: NA) on 201208.Sometime after starting the treatment, the patient complained of the following side effect(s):
  • Erythema Nodosum
  • Myositis
  • Off Label Use
A possible interaction with other drugs could have contributed to this reaction:
  • Decapeptyl
The patient was hospitalized.Establishing a causal relationship between a specific drug and consumer's side effects is complex, but it is possible that in this report Estreva treatment could be related to the listed above side effect(s).

Meningioma, Visual Impairment, Visual Acuity Reduced
This is a report of the following Estreva 0.1% Gel side effect(s):
  • Meningioma
  • Visual Impairment
  • Visual Acuity Reduced
A 60-year-old female patient from FR (weight: NA) presented with the following condition: NA and received a treatment with Estreva 0.1% Gel (dosage: 3 Dosage Forms Daily;) starting: NS.The following concurrently used drugs could have generated interactions:
  • Androcur (50 Milligram Daily;)
The patient was hospitalized.This report suggests that a Estreva 0.1% Gel treatment could be associated with the listed above side effect(s).

Optic Neuritis
This Estreva report was submitted by a 60-year-old female consumer from FR (weight: NA). The patient was diagnosed with: NA and Estreva was administered (dosage: 1 Milligram Daily;) starting: 201209. The consumer developed a set of symptoms:
  • Optic Neuritis
Other drugs used simultaneously:
  • Duphaston
  • Tahor (40 Milligram Daily;)
  • Monotildiem Lp (200 Milligram Daily;)
  • Eztrol (1 Dosage Forms Daily;)
  • Kardegic (75 Milligram Daily;)
  • Natispray (If Needed)
The patient was hospitalized.Those unexpected symptoms could be linked to a Estreva treatment, however establishing a potential drug-safety problem requires a more detailed clinical analysis.

Meningitis Aseptic, Cystitis
This is a report of a possible correlation between Estreva use and the following symptoms/side effect(s):
  • Meningitis Aseptic
  • Cystitis
which could contribute to an assessment of Estreva risk profile.A 46-year-old female consumer from FR (weight: NA) was suffering from NA and was treated with Estreva (dosage: NA) starting NS.Other concurrent medications:
  • Spifen
  • Estima
  • Carbosymag
  • Spagulax
The patient was hospitalized.

Rash Scarlatiniform, Anxiety, Hypertensive Crisis, Asthenia, Arthralgia, Chills
A 57-year-old female patient from FR (weight: NA) presented with the following symptoms: NA and after a treatment with Estreva (dosage: NA) experienced the following side effect(s):
  • Rash Scarlatiniform
  • Anxiety
  • Hypertensive Crisis
  • Asthenia
  • Arthralgia
  • Chills
The treatment was started on 2002. Estreva was used in combination with the following drugs:
  • Preterax (1 Dosage Forms Daily;)
  • Physiotens
  • Mediator
  • Lipanthyl (1 Dosage Forms Daily;)
  • Micardis
  • Stagid
  • Utrogestan
The patient was hospitalized.This report could alert potential Estreva consumers.

Thrombocytopenia, Idiopathic Thrombocytopenic Purpura
In this report, a 27-year-old female patient from FR (weight: NA) was affected by a possible Estreva side effect.The patient was diagnosed with acne. After a treatment with Estreva (dosage: Long Term Treatment, start date: NS), the patient experienced the following side effect(s):
  • Thrombocytopenia
  • Idiopathic Thrombocytopenic Purpura
The following simultaneously used drugs could have led to this reaction:
  • Androcur (Long Term Treatment)
The patient was hospitalized.The findings here stress that side effects should be taken into consideration when evaluating a Estreva treatment.

Meningioma
This is a report of a 50-year-old female patient from FR (weight: NA), who used Estreva (dosage: 2 Pressions From Day 21 To Day 28) for a treatment of NA. After starting a treatment on 199704, the patient experienced the following side effect(s):
  • Meningioma
The following drugs could possibly have interacted with the Estreva treatment
  • Androcur (25 Milligram Daily; 0.5 Tablet From Day 21 To Day 28 Of Each Cycle)
  • Androcur (25 Milligram Daily; 25 Mg From Day 10 To Day 21 Of Each Cycle)
  • Androcur (50 Milligram Daily; 50 Mg From Day 10 To Day 21 Of Each Cycle)
  • Oesclim
The patient was hospitalized.Taken together, these observations suggest that a Estreva treatment could be related to side effect(s), such as Meningioma.

Meningioma
This meningioma side effect was reported by a health professional from FR. A 46-year-old female patient (weight:NA) experienced the following symptoms/conditions: NA. The patient was prescribed Estreva (dosage: NA), which was started on 2006. Concurrently used drugs:
  • Androcur
  • Androcur
  • Androcur (For 10 Days Every Month)
When starting to take Estreva the consumer reported the following symptoms:
  • Meningioma
These side effects may potentially be related to Estreva.

Pulmonary Arterial Hypertension
This is a Estreva side effect report of a 75-year-old female patient (weight:NA) from FR, suffering from the following symptoms/conditions: NA, who was treated with Estreva (dosage:NA, start time: May 10, 2011), combined with:
  • Mediator
  • Mediator
  • Mediator
  • Arcoxia (1 Dosage Forms Daily;)
  • Avlocardyl (60 Milligram Daily;)
  • Levothyrox (80 Microgram Daily;)
  • Utrogestan
  • Flexea
, and developed a serious reaction and a pulmonary arterial hypertension side effect. The patient presented with:
  • Pulmonary Arterial Hypertension
which developed after the beginning of treatment. The patient was hospitalized. This side effect report can indicate a possible existence of increased vulnerability to Estreva treatment in female patients suffering from NA, resulting in pulmonary arterial hypertension.

Pulmonary Arterial Hypertension
This report suggests a potential Estreva 0,1 %, Gel pulmonary arterial hypertension side effect(s) that can have serious consequences. A 75-year-old female patient from FR (weight:NA) was diagnosed with the following health condition(s): NA and used Estreva 0,1 %, Gel (dosage: NA) starting May 10, 2011. Soon after starting Estreva 0,1 %, Gel the patient began experiencing various side effects, including:
  • Pulmonary Arterial Hypertension
Drugs used concurrently:
  • Mediator 150 Mg, Comprime Enrobe
  • Mediator 150 Mg, Comprime Enrobe
  • Mediator 150 Mg, Comprime Enrobe
  • Arcoxia (1 Dosage Forms Daily;)
  • Avlocardyl (60 Milligram Daily;)
  • Levothyrox (80 Microgram Daily;)
  • Utrogestan
  • Flexea
The patient was hospitalized. Although Estreva 0,1 %, Gel demonstrated significant improvements in a number of clinically relevant cases, troublesome symptoms, such as pulmonary arterial hypertension, may still occur.

Leukocytoclastic Vasculitis
This leukocytoclastic vasculitis problem was reported by a consumer or non-health professional from GERMANY. A 76-year-old female patient (weight: NA) was diagnosed with the following medical condition(s): NA.On Jul 26, 2009 a consumer started treatment with Estreva (dosage: NA). The following drugs/medications were being taken at the same time:
  • Irbesartan
  • Hydrochlorothiazide
  • Irbesartan
When commencing Estreva, the patient experienced the following unwanted symptoms /side effects:
  • Leukocytoclastic Vasculitis
The patient was hospitalized. Although all drugs are carefully tested before they are licensed for use, they carry potential side effect risks. Some side effects, such as leukocytoclastic vasculitis, may become evident only after a product is in use by the general population.

Fatigue, Renal Failure, Irritability
This is a Estreva Gel side effect report of a 52-year-old female patient (weight: NA) from FRANCE. The patient developed the following symptoms/conditions: NA and was treated with Estreva Gel (dosage: NA) starting Jan 01, 2004. Concurrently used drugs:
  • Zyprexa (10mg Per Day)
  • Androcur
  • Lamictal
Soon after that, the consumer experienced the following of symptoms:
  • Fatigue
  • Renal Failure
  • Irritability
This opens a possibility that Estreva Gel could cause fatigue and that some female patients may be more susceptible.



Top 10 Estreva Side Effects for Men

Men Side EffectsReports

Keep Track of Side Effects

Note Your Observations

It is really important to keep of your symptoms, right from the time you start a new medicine. You can do it any way you prefer: in a notebook, in a computer file or using our online tool. You should also note down any other medicines you are taking at the same time, because there could be an interaction between these medicines.

Why Your Notes are Important

Your notes could be helpful in several ways:

  • You can use them to remind you of details that may alert your health care professional(s) to a problem
  • You will have a record to refer to in the future, in case you are ever prescribed the same medicine again

  • Log Form

    You can use the following log form to write down important information, like the date and time you experienced a side effect and your symptoms, how strong the symptoms were, and any other medicines you were using.

    Medicine Name and Dosage:
    Side Effects Scale Date & Time Other Medicine(s) or Treatment(s)
    Scale: 1 = very mild to 10 = very bad

    You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


    Discuss Estreva Side Effects

    Did You Have a Estreva Side Effect?

    Yes, Severe
    Yes, Moderate
    Yes, Minor
    No

    How Effective is Estreva for You?

    Exceeded Expectations
    Effective
    Somewhat Effective
    Not Effective

    Estreva Safety Alerts, Active Ingredients, Usage Information

    More About Estreva

    Side Effects reported to FDA: 18

    Estreva safety alerts: No

    Reported hospitalizations: 10

    Latest Estreva clinical trials

    Estreva Reviews

    No reviews, be a first to report a side effect via side effect reporting form